Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL BUKHALO

Allopathic & Osteopathic Physicians Dermatology

NPI
1548239734
CMS profile
160228
Location
ROLLING MEADOWS, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$14,095.42

87 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL BUKHALO

NPI 1548239734 · CMS profile ID 160228

Allopathic & Osteopathic Physicians / Dermatology

ROLLING MEADOWS, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548239734?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL BUKHALO, NPI 1548239734, CMS profile ID 160228. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548239734?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MICHAEL BUKHALO, NPI 1548239734, CMS profile ID 160228. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548239734?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MICHAEL BUKHALO, NPI 1548239734, CMS profile ID 160228, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1548239734?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

87 matching records · $14,095.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 87 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–87 of 87.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $1,000.0005/05/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741420969 CMS
AbbVie Inc. $18.8804/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721713685 CMS
Genentech USA, Inc. $19.9504/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743063544 CMS
VYNE Pharmaceuticals Inc. $18.4204/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753204159 CMS
AbbVie Inc. $20.8904/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721713683 CMS
Janssen Biotech, Inc. $17.0204/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719311413 CMS
MAYNE PHARMA INC. $14.0204/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719709995 CMS
Galderma Laboratories, L.P. $12.8204/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726833387 CMS
VYNE Pharmaceuticals Inc. $20.8704/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753204175 CMS
Amgen Inc. $22.5703/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741420961 CMS
VYNE Pharmaceuticals Inc. $17.3903/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753204181 CMS
AbbVie Inc. $22.8903/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721713681 CMS
Novartis Pharmaceuticals Corporation $24.0203/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725611271 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $16.6703/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737457273 CMS
VYNE Pharmaceuticals Inc. $1.1002/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753204157 CMS
VYNE Pharmaceuticals Inc. $23.1402/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753204177 CMS
Amgen Inc. $18.2302/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741420957 CMS
Sun Pharmaceutical Industries Inc. $20.9402/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728249407 CMS
AbbVie Inc. $2,500.0002/17/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721713679 CMS
PFIZER INC. $12.0202/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743092725 CMS
AbbVie Inc. $16.0602/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721713677 CMS
Novartis Pharmaceuticals Corporation $1,500.0002/13/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725611247 CMS
AbbVie Inc. $391.6102/12/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721713675 CMS
Amgen Inc. $1,500.0002/11/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741420963 CMS
Novartis Pharmaceuticals Corporation $22.9302/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725611263 CMS
UCB, Inc. $21.4102/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746071275 CMS
Novartis Pharmaceuticals Corporation $1,500.0002/06/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725611237 CMS
Amgen Inc. $20.9002/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741420959 CMS
Sun Pharmaceutical Industries Inc. $15.9002/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728249413 CMS
Galderma Laboratories, L.P. $11.5801/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726833383 CMS
VYNE Pharmaceuticals Inc. $21.6101/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753204173 CMS
Regeneron Healthcare Solutions, Inc. $19.6401/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724415331 CMS
AbbVie Inc. $22.6501/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721713673 CMS
Novartis Pharmaceuticals Corporation $22.4001/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725611255 CMS
Sun Pharmaceutical Industries Inc. $20.9401/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728249409 CMS
UCB, Inc. $16.4501/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746067221 CMS
AbbVie Inc. $15.8801/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721713671 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $46,447.67 136
PY2020 $14,095.42 87
PY2021 $17,423.66 97
PY2022 $3,778.61 66
PY2023 $2,280.63 57
PY2024 $2,874.11 91
PY2025 $1,808.85 79

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $564,917.42 27
PY2025 Principal investigator $773,766.59 108
PY2024 Recipient $191,449.90 16
PY2024 Principal investigator $1,167,638.73 147
PY2023 Recipient $135,445.52 10
PY2023 Principal investigator $774,440.38 97
PY2022 Principal investigator $851,683.60 141
PY2021 Principal investigator $864,641.68 93
PY2020 Recipient $14,771.10 2
PY2020 Principal investigator $910,980.41 92
PY2019 Recipient $134,930.01 18
PY2019 Principal investigator $1,384,708.19 63

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

135 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $6,500.00 12/30/2025 Non-covered Recipient Entity
BUKHALO MICHAEL MD
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187877799
Principal investigator 1 Janssen Research & Development, LLC $2,533.00 12/25/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175334174
Principal investigator 1 Janssen Research & Development, LLC $2,854.00 12/22/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175334237
Principal investigator 1 Janssen Research & Development, LLC $8,005.00 12/19/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334407
Recipient Takeda Pharmaceuticals U.S.A., Inc. $47,376.00 12/19/2025 Covered Recipient Physician TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262800
Principal investigator 1 Janssen Research & Development, LLC $5,028.00 12/15/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334351
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $640.00 12/15/2025 Non-covered Recipient Entity
Arlington Dermatology
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051807
Principal investigator 1 ABBVIE INC. $14,590.20 12/04/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202526694
Principal investigator 1 ABBVIE INC. $14,527.05 12/04/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202526696
Principal investigator 1 ABBVIE INC. $2,994.40 12/04/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202526698
Principal investigator 1 Janssen Research & Development, LLC $2,524.00 12/01/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175334200
Recipient Takeda Pharmaceuticals U.S.A., Inc. $11,065.60 12/01/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262798
Principal investigator 1 ABBVIE INC. $7,863.60 11/05/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202522917
Principal investigator 1 ABBVIE INC. $17,658.80 11/05/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202522919
Principal investigator 1 ABBVIE INC. $5,836.45 11/05/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522987
Principal investigator 1 ABBVIE INC. $2,994.40 11/04/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202521115
Recipient Takeda Pharmaceuticals U.S.A., Inc. $40,574.80 11/03/2025 Covered Recipient Physician TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262796
Principal investigator 1 Janssen Research & Development, LLC $5,387.00 10/31/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175334342
Principal investigator 1 Janssen Research & Development, LLC $1,427.00 10/31/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175334383
Principal investigator 1 Janssen Research & Development, LLC $5,097.00 10/27/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334282
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,440.00 10/27/2025 Non-covered Recipient Entity
Arlington Dermatology
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051805
Principal investigator 1 Janssen Research & Development, LLC $22,522.60 10/23/2025 Non-covered Recipient Entity
Arlington Derm
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175215298
Recipient Takeda Pharmaceuticals U.S.A., Inc. $17,969.00 10/22/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262794
Principal investigator 1 ABBVIE INC. $12,422.60 10/09/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202516323
Principal investigator 1 ABBVIE INC. $1,312.40 10/09/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202516325
Principal investigator 1 ABBVIE INC. $4,667.40 10/09/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202516327
Principal investigator 1 ABBVIE INC. $11,797.75 10/09/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202516329
Recipient Takeda Pharmaceuticals U.S.A., Inc. $24,325.00 10/03/2025 Covered Recipient Physician TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262792
Recipient Takeda Pharmaceuticals U.S.A., Inc. $18,529.00 10/01/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262790
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,640.00 09/30/2025 Non-covered Recipient Entity
Arlington Dermatology
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051803
Principal investigator 1 Janssen Research & Development, LLC $1,683.00 09/29/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175334221
Principal investigator 1 Janssen Research & Development, LLC $6,310.00 09/29/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334439
Principal investigator 1 Janssen Research & Development, LLC $3,840.00 09/22/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334414
Recipient Takeda Pharmaceuticals U.S.A., Inc. $4,926.04 09/10/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262788
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,080.00 09/08/2025 Non-covered Recipient Entity
Arlington Dermatology
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051801
Principal investigator 1 ABBVIE INC. $9,760.25 09/04/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509482
Principal investigator 1 ABBVIE INC. $3,457.80 09/04/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202509484
Principal investigator 1 ABBVIE INC. $17,670.40 09/04/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202509486
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,400.00 09/04/2025 Non-covered Recipient Entity
Arlington Dermatology
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235998918
Principal investigator 1 Janssen Research & Development, LLC $4,464.00 09/04/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175334205
Principal investigator 1 ABBVIE INC. $2,624.80 09/03/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202507905
Recipient Takeda Pharmaceuticals U.S.A., Inc. $25,355.40 09/03/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262786
Principal investigator 1 Janssen Research & Development, LLC $5,760.00 09/01/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334212
Recipient Takeda Pharmaceuticals U.S.A., Inc. $28,981.40 08/22/2025 Covered Recipient Physician TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262784
Recipient Takeda Pharmaceuticals U.S.A., Inc. $4,926.04 08/13/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262782
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,560.00 08/07/2025 Non-covered Recipient Entity
Arlington Dermatology
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051799
Principal investigator 1 ABBVIE INC. $28,124.70 08/06/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202502807
Principal investigator 1 ABBVIE INC. $15,081.25 08/06/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202502809
Principal investigator 1 ABBVIE INC. $11,383.80 08/06/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502811
Principal investigator 1 ABBVIE INC. $1,312.40 08/05/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD DBA ARLINGTON DERMATOLOGY
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202501530
Principal investigator 1 Janssen Research & Development, LLC $3,366.00 08/04/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175334362
Recipient Takeda Pharmaceuticals U.S.A., Inc. $28,245.00 08/01/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262778
Recipient Takeda Pharmaceuticals U.S.A., Inc. $25,825.80 08/01/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262780
Principal investigator 1 Janssen Research & Development, LLC $29,635.00 07/31/2025 Non-covered Recipient Entity
Arlington Derm
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175215305
Principal investigator 1 Janssen Research & Development, LLC $2,328.00 07/28/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334392
Principal investigator 1 Janssen Research & Development, LLC $4,803.00 07/28/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175334424
Recipient Takeda Pharmaceuticals U.S.A., Inc. $10,425.57 07/18/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262776
Principal investigator 1 Janssen Research & Development, LLC $1,427.00 07/10/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175334327
Principal investigator 1 ABBVIE INC. $23,757.40 07/08/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202497284
Principal investigator 1 ABBVIE INC. $5,945.40 07/08/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497286
Principal investigator 1 ABBVIE INC. $1,152.60 07/02/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202495387
Principal investigator 1 ABBVIE INC. $9,659.50 07/02/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202495505
Principal investigator 1 ABBVIE INC. $1,497.20 07/02/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD DBA ARLINGTON DERMATOLOGY
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202495507
Principal investigator 1 Janssen Research & Development, LLC $6,984.00 06/30/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334267
Principal investigator 1 Janssen Research & Development, LLC $7,652.00 06/27/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334334
Principal investigator 1 Janssen Research & Development, LLC $1,262.00 06/26/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175334305
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $16,850.00 06/23/2025 Non-covered Recipient Entity
Arlington Dermatology
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051797
Recipient Takeda Pharmaceuticals U.S.A., Inc. $29,246.00 06/13/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262774
Recipient Takeda Pharmaceuticals U.S.A., Inc. $5,624.67 06/11/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262772
Principal investigator 1 Janssen Research & Development, LLC $1,427.00 06/09/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175334192
Principal investigator 1 ABBVIE INC. $2,994.40 06/03/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD DBA ARLINGTON DERMATOLOGY
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202489291
Principal investigator 1 ABBVIE INC. $7,054.00 06/03/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489293
Principal investigator 1 ABBVIE INC. $17,887.00 06/03/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202489295
Principal investigator 1 ABBVIE INC. $4,605.00 06/03/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202489381
Principal investigator 1 Janssen Research & Development, LLC $9,904.00 05/26/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334311
Principal investigator 1 Janssen Research & Development, LLC $1,913.00 05/26/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334431
Principal investigator 1 Janssen Research & Development, LLC $2,304.00 05/22/2025 Non-covered Recipient Entity
Arlington Derm
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175215268
Principal investigator 1 Janssen Research & Development, LLC $5,699.00 05/22/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175334260
Recipient Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 05/14/2025 Covered Recipient Physician TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262768
Recipient Takeda Pharmaceuticals U.S.A., Inc. $9,249.31 05/14/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262770
Principal investigator 1 Janssen Research & Development, LLC $3,422.00 05/09/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175334356
Principal investigator 1 Janssen Research & Development, LLC $19,559.10 05/08/2025 Non-covered Recipient Entity
Arlington Derm
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175215315
Principal investigator 1 ABBVIE INC. $18,287.80 05/07/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202483081
Principal investigator 1 ABBVIE INC. $13,830.50 05/07/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483083
Principal investigator 1 ABBVIE INC. $9,612.00 05/07/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483085
Recipient Takeda Pharmaceuticals U.S.A., Inc. $31,533.60 05/07/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262766
Principal investigator 1 ABBVIE INC. $1,497.20 05/06/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD DBA ARLINGTON DERMATOLOGY
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202481689
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,250.00 05/01/2025 Non-covered Recipient Entity
Arlington Dermatology
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051795
Principal investigator 1 Janssen Research & Development, LLC $1,262.00 04/28/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175334245
Principal investigator 1 Janssen Research & Development, LLC $4,380.00 04/28/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334319
Principal investigator 1 Janssen Research & Development, LLC $7,422.00 04/25/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334275
Recipient Takeda Pharmaceuticals U.S.A., Inc. $12,999.09 04/11/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262762
Recipient Takeda Pharmaceuticals U.S.A., Inc. $58,858.80 04/11/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262764
Principal investigator 1 Eli Lilly and Company $28,617.40 04/10/2025 Non-covered Recipient Entity
BUKHALO MICHAEL MD
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187876167
Principal investigator 1 ABBVIE INC. $9,546.25 04/03/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202473089
Principal investigator 1 ABBVIE INC. $16,577.80 04/03/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202473101
Principal investigator 1 ABBVIE INC. $1,315.80 04/03/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202473604
Principal investigator 1 ABBVIE INC. $1,312.40 04/03/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD DBA ARLINGTON DERMATOLOGY
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202473609
Principal investigator 1 Janssen Research & Development, LLC $1,913.00 03/27/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175334375
Principal investigator 1 Janssen Research & Development, LLC $11,164.00 03/24/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334291
Principal investigator 1 Janssen Research & Development, LLC $2,474.00 03/21/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334446
Recipient Takeda Pharmaceuticals U.S.A., Inc. $13,320.39 03/14/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262760
Principal investigator 1 ABBVIE INC. $6,915.60 03/07/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202460144
Principal investigator 1 ABBVIE INC. $8,200.50 03/07/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
M24-727 - A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202460148
Principal investigator 1 ABBVIE INC. $8,119.75 03/07/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460281
Principal investigator 1 ABBVIE INC. $2,115.00 03/06/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202457096
Principal investigator 1 ABBVIE INC. $3,937.20 03/06/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD DBA ARLINGTON DERMATOLOGY
M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202457228
Principal investigator 1 Janssen Research & Development, LLC $3,990.00 03/06/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175334400
Principal investigator 1 Janssen Research & Development, LLC $3,933.00 03/03/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334229
Principal investigator 1 Janssen Research & Development, LLC $7,865.00 03/03/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334298
Principal investigator 1 Janssen Research & Development, LLC $10,376.00 03/03/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175334454
Recipient Takeda Pharmaceuticals U.S.A., Inc. $57,997.80 02/26/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262758
Principal investigator 1 Incyte Corporation $1,417.50 02/21/2025 Non-covered Recipient Entity
ARLINGTON DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240503342
Recipient Takeda Pharmaceuticals U.S.A., Inc. $26,645.92 02/12/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262756
Principal investigator 1 ABBVIE INC. $10,291.20 02/06/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202448135
Principal investigator 1 ABBVIE INC. $12,476.25 02/06/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202448142
Principal investigator 1 Janssen Research & Development, LLC $5,836.00 02/06/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334185
Principal investigator 1 ABBVIE INC. $513.50 02/05/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202444839
Principal investigator 1 Incyte Corporation $4.25 02/05/2025 Non-covered Recipient Entity
ARLINGTON DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240503330
Principal investigator 1 Incyte Corporation $93.30 02/05/2025 Non-covered Recipient Entity
ARLINGTON DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240503334
Principal investigator 1 Incyte Corporation $52.48 02/05/2025 Non-covered Recipient Entity
ARLINGTON DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240503338
Principal investigator 1 Incyte Corporation $77.75 02/05/2025 Non-covered Recipient Entity
ARLINGTON DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240503346
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 01/31/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175334369
Principal investigator 1 Janssen Research & Development, LLC $16,215.00 01/27/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175334253
Principal investigator 1 Incyte Corporation $1,109.60 01/24/2025 Non-covered Recipient Entity
ARLINGTON DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240503317
Principal investigator 1 Incyte Corporation $1,575.00 01/24/2025 Non-covered Recipient Entity
ARLINGTON DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240503321
Principal investigator 1 Incyte Corporation $1,675.00 01/24/2025 Non-covered Recipient Entity
ARLINGTON DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240503326
Principal investigator 1 Janssen Research & Development, LLC $25,024.71 01/23/2025 Non-covered Recipient Entity
Arlington Derm
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175215284
Principal investigator 1 Janssen Research & Development, LLC $3,024.00 01/23/2025 Non-covered Recipient Entity
Arlington Derm
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175215290
Recipient Takeda Pharmaceuticals U.S.A., Inc. $3,749.78 01/17/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262754
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,755.00 01/08/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262748
Recipient Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 01/08/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262750
Recipient Takeda Pharmaceuticals U.S.A., Inc. $13,612.41 01/08/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223262752
Principal investigator 1 ABBVIE INC. $1,497.20 01/02/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD DBA ARLINGTON DERMATOLOGY
M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 1202434572
Principal investigator 1 ABBVIE INC. $1,707.00 01/02/2025 Non-covered Recipient Entity
MICHAEL BUKHALO MD SC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202434577